Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

1.4%

1 terminated/withdrawn out of 70 trials

Success Rate

98.4%

+11.9% vs industry average

Late-Stage Pipeline

37%

26 trials in Phase 3/4

Results Transparency

10%

6 of 63 completed trials have results

Key Signals

3 recruiting6 with results

Enrollment Performance

Analytics

Phase 1
24(36.9%)
Phase 3
17(26.2%)
Phase 2
10(15.4%)
Phase 4
9(13.8%)
N/A
5(7.7%)
65Total
Phase 1(24)
Phase 3(17)
Phase 2(10)
Phase 4(9)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (70)

Showing 20 of 70 trials
NCT05177484Phase 3Completed

Perioperative Iron for Colorectal Cancer (PICoC Study)

Role: collaborator

NCT07218523Phase 3Recruiting

A Study to Investigate Bowel Cleansing With PLENVU® Compared to Sodium Picosulfate in Participants Aged 1 to < 18 Years of Age in Preparation for Colonoscopy

Role: lead

NCT02065726Not ApplicableCompleted

Whey Protein Supplementation in Cancer Patients

Role: collaborator

NCT05697211Phase 4Completed

ORal IrON Supplementation with Ferric Maltol in Treating Iron Deficiency and Anaemia in Patients with Heart Failure (ORION-HF)

Role: collaborator

NCT04073290Phase 4Recruiting

Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose

Role: collaborator

NCT05436054Phase 4Recruiting

A Trial to Compare Efficacy and Tolerability of Plenvu® and Picoprep® as Cleansing Agents Before Colonoscopy

Role: collaborator

NCT00794716Phase 2Completed

PK of NRL972 in Patients with Nonalcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD)

Role: lead

NCT06593743Phase 1Completed

The Safety and Dose Response to Single Anal Doses of NRL001

Role: lead

NCT06597903Phase 2Completed

A Monocentric Study to Investigate a New Low Dose Oral Gut Cleansing Solution

Role: lead

NCT01710982Phase 3Completed

Study to Evaluate the Safety of Post-Operative TZP-101 (IV Ulimorelin) After Partial Bowel Resection

Role: lead

NCT06593730Phase 1Completed

Safety and Tolerability of the Twice Daily Intra-anal Application of NRL001 Cream for 14 Days

Role: lead

NCT03437265Phase 1Completed

A Pharmacokinetic Study of PLENVU® in Healthy Subjects

Role: lead

NCT03442738Completed

A Prospective Randomized Comparison of the Adenoma Detection Rate With a Disposable Cap (ENDOCUFF VISION®)

Role: collaborator

NCT05174845Completed

Real Word Evidence With 1L Polyethylene Glycol (PEG)+ Ascorbic Acid in Iberia

Role: lead

NCT04070677Not ApplicableUnknown

Clinical Study Assessing the Effect of ZIVEREL® in Cancer Patients

Role: collaborator

NCT04487912Phase 4Withdrawn

Dynamics and Tracer Distribution of Tilmanocept in Early Stage Breast Cancer

Role: collaborator

NCT02081742Completed

Comparative Study of Colon Capsule and Virtual Colonoscopy (VICOCA)

Role: collaborator

NCT02488993Completed

Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin (PROSPER)

Role: lead

NCT03072472Not ApplicableCompleted

BowelScope: Accuracy of Detection Using ENdocuff Optimisation of Mucosal Abnormalities

Role: collaborator

NCT02273167Phase 3Completed

Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.

Role: lead